Lyra Therapeutics’ $56 Million Initial Public Offering

Latham & Watkins LLP represents Lyra Therapeutics on the transaction

Lyra Therapeutics, Inc. (Nasdaq: LYRA) has announced the pricing of its initial public offering of 3,500,000 shares of common stock at a public offering price of $16.00 per share, before deducting underwriting discounts and commissions. All of the common stock is being offered by Lyra. The offering is expected to close on May 5, 2020, subject to customary closing conditions. In addition, Lyra has granted the underwriters a 30-day option to purchase up to an additional 525,000 shares of its common stock at the initial public offering price less the underwriting discounts and commissions. The gross proceeds of the offering are expected to be $56.0 million, excluding any exercise of the underwriters’ option.

Latham & Watkins LLP represents Lyra Therapeutics in the initial public offering with a capital markets team led by Boston partners Peter Handrinos (Picture) and Wesley Holmes with New York associates Samuel Niles, Thomas Gabay and Shawn Noh. Advice was also provided on FDA regulatory matters by Washington, D.C. partners John Manthei and Ben Haas with associate Eitan Bernstein; on healthcare regulatory matters by Bay Area counsel Betty Pang with Washington, D.C. associate Margaret Rote; on intellectual property matters by New York partner Alan Tamarelli with associate Jiqiang Lin; on benefits and compensation matters by Washington, D.C. partner Matthew Conway with Boston associate Lilly Fang; and on tax matters by Washington, D.C. partner Andrea Ramezan- Jackson with associate Pierce Pandolph

Involved fees earner: Eitan Bernstein – Latham & Watkins; Matthew Conway – Latham & Watkins; Lilly Fang – Latham & Watkins; Thomas Gabay – Latham & Watkins; Ben Haas – Latham & Watkins; Peter Handrinos – Latham & Watkins; Wesley Holmes – Latham & Watkins; Jiqiang Lin – Latham & Watkins; John Manthei – Latham & Watkins; Samuel Niles – Latham & Watkins; Sang Hyun Noh – Latham & Watkins; Pierce Pandolph – Latham & Watkins; Betty Pang – Latham & Watkins; Andrea Ramezan-Jackson – Latham & Watkins; Alan Tamarelli Jr. – Latham & Watkins;

Law Firms: Latham & Watkins;

Clients: Lyra Therapeutics Inc.;

Author: Ambrogio Visconti